To demonstrate that PredictSURE IBD can stratify an ethnically diverse North American population into high and low risk based on the need for early and frequent treatment escalations in the high-risk cohort.

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).

The purpose of the GRAVITI Study is to evaluate the efficacy and safety of the investigational study medication in participants with moderately to severely active Crohn's disease.

The objective of the Boomerang Clinical Trial is to evaluate the safety and performance of our neurostimulator medical device in patients with Crohn’s disease and left-sided ulcerative colitis and to identify patients who are most likely to benefit from treatment.

The hypothesis of this study is that the appropriate time of day of administration of oral, once-daily 5-ASA therapy in alignment with the participant’s circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels.

To understand the most important priorities of IBD patients who need surgery and quantify the reasons why patients consider delaying surgery, with potential reasons including, but not limited to lack of psychosocial support, gaps in knowledge, social stigma, burden to daily life, financial reasons, concerns about fertility, and mental well-being.

To assess the efficacy, safety, and tolerability of the investigational drug in comparison with placebo in participants with moderately to severely active CD who had inadequate response to or were intolerant of prior biologics.

Primary Objective: Safety and Tolerability

Secondary Objective: Efficacy

The primary goal of this study is to demonstrate the efficacy and safety of brazikumab in participants with moderately to severely active CD and demonstrate the clinical utility of a serum biomarker to identify participants who are most likely to benefit from treatment with brazikumab.

The purpose of this study is to evaluate the efficacy and safety of brazikumab versus placebo to induce clinical remission based on endoscopic improvement, rectal bleeding, and stool frequency scores in participants with moderate to severe UC who have failed or are intolerant to conventional therapy.